High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis

Sun, Yifan; Wu, Zhitong; Wei, Lili; Liu, Chunming; Zhu, Shengbo; Tang, Shifu

doi:10.3109/09513590.2015.1056140

Cited by 44 publications

(23 citation statements)

References 39 publications

(51 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Visfatin is a proinflammatory adipokine involved in inflammation, and the upregulation of this adipokine leads to the development of a chronic low-grade inflammatory state. This biomarker has been studied for several inflammatory diseases such as obesity, metabolic syndrome, type 2 DM, polycystic ovary syndrome, and RA, but the findings are controversial [10][11][12][13][16][17][18]. Subsequent studies described visfatin upregulation in several immune cells including monocytes, lymphocytes, dendritic cells and macrophages [19][20][21].…”

Section: Discussionmentioning

confidence: 99%

“…It is limiting enzyme in nicotinamid adenine dinucleotide (NAD) synthesis and as such known as nicotinamid phosphoribosyl transferase (NAMPT) [8]. Visfatin has been proposed as a new marker of inflammation in diabetes mellitus (DM), metabolic syndrome, polycystic ovary syndrome, coronary artery disease, and rheumatoid arthritis (RA) [9][10][11][12][13]. Visfatin was shown to induce the secretion of proinflammatory cytokines including TNF-α, IL-6 and IL-8,while these cytokins could induce the expression of visfatin [14].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?

Tanrıverdi

Iliaz

Çörtük

et al. 2017

Diffuse Parenchymal Lung Disease

View full text Add to dashboard Cite

Objective: Sarcoidosis is a chronic systemic inflammatory disease which can affect multiple organ systems. The role of biomarkers in the diagnosis and prognosis of sarcoidosis is increasing. Interest in the role of adipose tissue mediated inflammation in the pathogenesis of the inflammatory diseases has increased in recent years. Visfatin is a proinflammatory adipocytokine which has been studied for several inflammatory diseases such as diabetes mellitus, obesity and metabolic syndrome. Our aim is to assess serum visfatin levels in sarcoidosis and its relation with other markers of inflammation (CRP, ACE and ESR). Material and Methods: We enrolled 59 patients with sarcoidosis and 21 healthy controls. We measured plasma levels of visfatin along with serum CRP, ESR, ACE using ELISA (enzyme-linked immunosorbent assay) kits (Blue Gene Biotech, Shanghai, China). Results: Visfatin levels were not significantly different between patients and control subjects (29.9±15.8 ng/ml for patients and 23.93±16.73 ng/ml for controls, p=0.15) and there was no correlation between visfatin and serum CRP, ACE or ESR in patients with sarcoidosis. Conclusion: Visfatin recently is being discussed as biomarker for inflammatory diseases in several studies and results are controversial. In our study, no differences were found in serum level of visfatin between patients with sarcoidosis and control group.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?

Tanrıverdi

Iliaz

Çörtük

et al. 2017

Diffuse Parenchymal Lung Disease

View full text Add to dashboard Cite

show abstract

“…Visfatin — also called nicotinamide phosphoribosyltransferase (NAMPT), or pre-B-cell colony-enhancing factor (PBEF) — is the most abundant adipokine secreted mainly from the visceral fat adipocytes, and it is positively correlated with body mass index (BMI). Visfatin is upregulated during adipocyte differentiation and has insulin-like activity under physiological conditions; hence, elevated visfatin levels have been found to be positive correlated with metabolic syndromes, such as polycystic ovary syndrome [7], type 2 diabetes mellitus (T2DM) [8], and cardiovascular diseases [9]. In addition, visfatin is also one of the inflammatory cytokines and can interact with interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α)[10].…”

Section: Introductionmentioning

confidence: 99%

Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma

Sun

Zhu

et al. 2017

Oncotarget

Self Cite

View full text Add to dashboard Cite

Visfatin is considered a pro-inflammatory adipocytokine, and it is commonly increased in obesity-related diseases. This study aimed to evaluate the levels of serum visfatin in patients with hepatocellular carcinoma (HCC) and its diagnostic and predictive value in detecting HCC. Fasting serum levels of visfatin of 135 HCC patients, 115 chronic hepatitis B (CHB) patients, 129 liver cirrhosis (LC) patients, and 149 healthy controls were determined via enzyme-linked immunosorbent assay. Meanwhile, serum alpha fetal protein (AFP) and interleukin-6 (IL-6) were also assayed. The median serum visfatin concentration in HCC patients was 1.113 ng/ mL (range: 0.823-2.214 ng/mL), which was significant higher than those of healthy controls, CHB patients, and LC patients (P<0.05). The serum visfatin concentration in HCC patients was positively correlated with AFP (r=0.595, P<0.001) and IL-6 (r=0.261, P<0.015) and was also associated with tumor size and tumor node metastasis stage. Moreover, elevated levels of serum visfatin were associated with a higher HCC risk for CHB and LC patients. Multivariate Cox regression analysis had shown that HCC patients with high levels of serum visfatin had significantly shorter overall survival times than those with low serum visfatin levels (P<0.001). Using a cutoff visfatin level of 1.403 ng/mL, the receiver operating characteristic curve analysis showed unappealing sensitivity and specificity values (45.76% and 74.79%, respectively; AUC=0.626) regarding visfatin's use as a diagnostic marker for HCC. Our results indicate that increased serum visfatin levels are associated with poor prognosis of HCC. Visfatin may be a potential therapeutic target of HCC.

show abstract

“…A meta-analysis [153] encompassing a study among 1341 women (695 with PCOS and 646 controls) showed higher visfatin levels in PCOS women without a significant correlation between it and BMI, HOMA-index, and testosterone. The authors concluded that high circulating visfatin can be perceived as a specific characteristic of PCOS, which even presupposes a role for this adipokine as a potential diagnostic biomarker for PCOS [153]. Kowalska et al [154] found higher visfatin levels and a reduced insulin sensitivity in both normal-weight and obese PCOS women in comparison to healthy controls.…”

Section: Visfatinmentioning

confidence: 99%

Clinical Impact of Insulin Resistance in Women with Polycystic Ovary Syndrome

Orbetzova¹

2020

Polycystic Ovarian Syndrome

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by multiple hormonal imbalances, reflecting on the clinical presentation. Among them, the insulin resistance (IR), defined as a metabolic state characterized by a decrease in cellular ability to respond to insulin signaling, is a key feature of PCOS independently of obesity. Thus, IR occurs in more than 70% of obese PCOS women and in 30-50% of lean ones. Compensatory high insulin levels are both a symptom and an underlying physiopathological driver of PCOS. Insulin appears to disrupt all components of the hypothalamic-pituitary-ovarian axis, and ovarian tissue IR results in impaired metabolic signaling but intact mitogenic and steroidogenic activity, favoring hyperandrogenemia. The latter is the main culprit of the clinical picture in PCOS. Testing for IR can be helpful to rule out other conditions that are commonly misdiagnosed as PCOS and to recommend an appropriate treatment for the different PCOS phenotypes.

show abstract

High-visfatin levels in women with polycystic ovary syndrome: evidence from a meta-analysis

Abstract: Our results indicate that high-circulating visfatin level is an intrinsic characteristic of PCOS, which suggests visfatin could be a potential biomarker for PCOS.

Cited by 44 publications

References 39 publications

The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?

The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis?

Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma

Clinical Impact of Insulin Resistance in Women with Polycystic Ovary Syndrome

Contact Info

Product

Resources

About